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Introduction
Carcinoma of the cervix remains the most frequent 
cancer a ecting women in South Africa. Twenty-three 
per cent of all reported cancers in women are of the 
uterine cervix. Cancer of the cervix resulted in an 
estimated 3 700 deaths in South Africa during 2002. 
The human papillomavirus (HPV) has been proven 
a potent carcinogen. The aetiological role of HPV 
infection in the development of preinvasive and 
invasive lesions of the cervix, vagina and the 
anogenital region has been conclusively established. 
Vaccination against infection with speci c high-risk 
HPV is commercially available, and is likely to change 
the future of the disease. 
Epidemiology and burden of disease
The HPV types most commonly associated with the 
development of malignant disease include HPV16 and 
HPV18 and, to a lesser degree, HPV31 and HPV45. HPV 
types are classi ed as high and low risk according to 
their association with cancer. The  ve most frequent 
HPV types among women with cervical cancer are 
HPV16, HPV18, HPV33, HPV45 and HPV31. 
Low-risk HPV (mainly HPV6 and HPV11) causes 
approximately 90% of genital warts, and there is 
possibly an aetiological association with recurrent 
juvenile laryngeal papillomatosis.
Preventing cervical cancer
Primary prevention
HPV infection is one of the most common sexually 
transmitted infections worldwide, a ecting more than 
70% of women in the USA and up to 95% of high-risk 
women in Africa.
Prophylactic HPV vaccines, protecting against certain 
oncogenic strains, are available and represent the most 
important advance in the  ght against cervical cancer, 
as a primary preventative strategy. 
Other factors include the reduction of smoking, both 
active and passive, to prevent cervical cancer. Recently, 
two other important additional strategies have also 
been shown to be of value. The use of condoms has 
been shown to signi cantly decrease the incidence 
of acquiring HPV infection. Condom use will decrease 
HPV infection by about 60%, but it will not eradicate 
infection totally. Of note is that HPV infection of the 
anogenital area does not only depend on penetrative 
sex, and that purely skin-to-skin contact is su  cient to 
cause infection. The other important strategy is male 
circumcision. This signi cantly decreases transmission 
of HPV from males to females.
Secondary prevention
Secondary prevention is aimed at screening the 
general population to identify those individuals at 
high risk of developing disease. Cervical cytology has 
been the most successful cancer prevention strategy 
in history, and has signi cantly reduced the number 
of new cases of invasive carcinoma. The sensitivity 
and speci city of a single cytology test are, however, 
often disappointingly low. Well-organised call and 
recall programmes are expensive. In South Africa, 
the national cytology programme has not had any 
signi cant impact on mortality statistics, and may 
never be successful in certain isolated populations with 
poor access to health care. 
High-risk HPV testing o ers several potential 
advantages over conventional cervical cytology in 
the setting of primary screening, but also has many 
limitations. HPV testing is signi cantly more sensitive 
than cytology in predicting cervical cancer and its 
precursors. It is apparent that HPV testing may be 
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a better test to use in programmes with once-in-a-
lifetime testing or long screening intervals (> 5 years). 
Longer screening intervals are more cost-e ective, 
overall.
Other strategies include visual inspection of the 
cervix after acetic acid application (VIA), which has a 
sensitivity of 67-79% and a speci city of 49-86%, and 
visual inspection of the cervix after Lugol’s iodine 
application (VILI), which has a sensitivity of 78-98% and 
a speci city of 73-93%.
Prophylactic HPV vaccination
The human papaillomavirus
HPV is a non-enveloped, double-stranded, 
deoxyribonucleic acid (DNA) virus. The genome of HPV 
is enclosed in a capsid shell made up of major (L1) and 
minor (L2) structural proteins. There are more than 
100 known genotypes of HPV, and certain (oncogenic) 
types are associated with cell transformation that leads 
to cancer. Certain high-risk HPV viruses have an a  nity 
for integrating certain areas of the viral genome into 
the host chromosomes. 
Pathology and immunology
HPV gains access to cervical tissue via skin abrasions 
and invades the basal layer, where it resides for the long 
term. A large percentage of the population will have 
sustained clinical remission, but a small proportion 
will develop persistent infection and become HPV-
DNA positive on repeated testing. Persistent infection 
with oncogenic strains of HPV can lead to high-grade 
squamous intraepithelial neoplasia or adenocarcinoma 
in situ (AIS). These precancerous lesions have a high 
probability of progressing to invasive squamous 
carcinoma or adenocarcinoma. 
HPV infection a ects the intraepithelial layer of 
the mucosa, and does not elicit a marked immune 
response. About 50% of women infected with HPV 
develop detectable serum antibodies, although these 
antibodies are not necessarily protective against 
subsequent reinfection by the same HPV type.
Prophylactic HPV vaccine
HPV virus-like particles (VLP) are used in the 
manufacturing of the currently available prophylactic 
vaccines. These vaccines contain no viral DNA capable 
of replication and are, therefore, non-infectious and 
cannot lead to disease. They induce antibody titres 
much higher than naturally occurring infections. 
The VLPs are combined with a non-speci c immune 
stimulant called an adjuvant, which leads to improved 
production of immunoglobulins against the vaccine 
types of VLPs. These speci c antibodies must be 
concentrated primarily within the cervicovaginal 
secretions to ultimately provide protection.
Currently, there are two registered prophylactic 
vaccines for HPV vaccination, namely Cervarix®, which 
contains HPV types 16 and 18, and Gardasil®, which 
protects against HPV16, HPV18 and low-risk types 6 
and 11. 
E  cacy
The quadrivalent prophylactic vaccine (Gardasil®) has 
been evaluated in two phase III randomised placebo-
controlled clinical trials designed to investigate its 
e  cacy. In women who had no prior evidence of 
infection, the vaccine was 98.2% e ective at 3.6 years 
against HPV16 and HPV18 cervical intraepithelial 
neoplasia (CIN) 2 or 3 lesions and adenocarcinoma 
in situ lesions. Gardasil® was 100% e ective against 
HPV6- and HPV11-related lesions. The quadrivalent 
vaccine also showed partial cross-protection to other 
vaccine types. There was also a signi cant reduction in 
colposcopy, cervical biopsy and de nitive therapy.
The e  cacy of the bivalent vaccine (Cervarix®) for 
protection against HPV16 and HPV18 CIN 2 lesions 
was 98.4%, and against HPV16- and HPV18-associated 
CIN 3 lesions it was 100%. There was also signi cant 
protection against non-vaccine oncogenic types 
[HPV33 (72.3%) and HPV45 (100%)]. The bivalent 
vaccine signi cantly decreased colposcopy referrals 
and cervical excision procedures.
Safety
The safety of the two HPV vaccines has been studied 
extensively during clinical trials. This has been closely 
monitored by governing bodies, including the Centers 
for Disease Control and Prevention (CDC) and the FDA 
(Food and Drug Administration) in the United States. 
The overwhelming opinion, from all the published data, 
is that both commercial HPV vaccines are extremely 
safe, without any proven serious risks. 
Non-serious events associated with HPV vaccination 
include fainting, pain and swelling at the injection site, 
headache, nausea and fever. There is no increase in the 
incidence of autoimmune disease, vascular thrombosis 
or other serious side-e ects. Of the deaths reported 
around the time of vaccination, none were considered 
to be associated with the vaccine.
Cost-e ectiveness of population-wide HPV 
vaccination in South Africa
A recent calculation of the cost-e ectiveness of 
introducing HPV vaccination in South Africa (Sinanovic, 
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2009) found that the price for the vaccine was the main 
cost driver. A price reduction of 60% or more would 
make vaccine-plus-screening more cost e ective than 
the screening-only option.
Ideal age of vaccination
Most authorities have recommended that HPV 
vaccination should be routinely o ered to females 
between 11 and 12 years, but it can be administered 
as young as nine years. Catch-up vaccination is 
recommended for females aged 13 to 26 years who 
have not been previously vaccinated. 
Data are now available to support that there is 
signi cant clinical e  cacy with Gardasil® vaccination 
in women up to 45 years of age, and immunogenic 
e  cacy with Cervarix® in women up to 55 years of age.
Testing before vaccination
Testing for HPV exposure before vaccination is currently 
not recommended. In general, no additional testing is 
required before vaccination, except where pregnancy 
may be a possibility. 
The HIV pandemic
Studies on HPV immunisation in HIV-infected 
individuals are not readily available. The e  cacy of 
HPV vaccination in immunocompromised individuals 
is largely unknown. 
Recommendations for implementation of HPV 
vaccines in SA
Population-wide HPV vaccination
In South Africa, an HPV immunisation programme 
should be planned, in order to reduce the cervical 
cancer epidemic. A coverage rate of over 70% is 
needed to impact on cervical cancer incidence. While 
this is a public health issue that should be addressed by 
Government, the South African Human Papillomavirus 
Advisory Board makes the following recommendations:
• Universal immunisation of young girls before the 
age of sexual debut. 
• Vaccination should be between nine and 12 years. 
• Both available vaccines require a multi-dosing 
schedule; three doses are recommended at 
months 0, 1-2 and 6.
Individual HPV immunisation before population-
wide HPV vaccination
• Teenaged females: Immunisation of young females, 
up to the age of 26 years, on an ad hoc basis is 
recommended. The prerequisites for this practice 
include a consenting, well-informed patient, 
 nancial a ordability, and information on cervical 
screening in future.
• Adult females: Neither HPV DNA testing of the 
cervical area, nor serological HPV antibody testing, 
proves non-contact with HPV. The entire adult 
female population should not be a primary target 
group for vaccination, although individuals may 
bene t from vaccination.
• Males: Routine vaccination of the male population is 
not currently recommended. However, individuals 
may bene t from vaccination and, in future, cost-
e ectiveness may be shown for disease prevention 
in men and/or women.
• High risk subgroups: It is di  cult to de ne and 
identify high-risk individuals. Not all individuals 
who are at high risk of HPV infection may bene t 
from HPV vaccination, although some individuals 
may. These groups should be targeted for genital 
cancer screening.
• HIV-positive individuals: Individuals who are infected 
by HIV are at an increased risk of developing HPV-
related cancers. A patient with an intact immune 
system can potentially bene t from vaccination, 
and this is considered a safe approach. However, 
in women with AIDS, the immune response will 
probably be insu  cient.The importance of regular 
screening is obvious.
• Post-exposure vaccination: Unless proven 
ine ective in further studies, immediate vaccination 
of rape survivors should be strongly considered.
Contraindications to vaccination
The safety of HPV vaccination in pregnancy has not 
been established. While initial trials reported no 
adverse e ects, single reports on vaccine reactions 
and side-e ects are appearing in the literature. These 
vaccines are, however, regarded as extremely safe.
Prophylactic vaccines used for therapeutic e ect
There is insu  cient evidence of a therapeutic bene t of 
the available prophylactic HPV vaccines in individuals 
with established infection or disease, and this usage is 
currently not recommended. 
Cervical cancer screening tests in conjunction 
with HPV vaccination
Continued cervical cancer screening will be needed 
for many decades to come. Not only will su  cient 
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population coverage take many years to be achieved, 
but all women, and particularly immunocompromised 
women, will require ongoing screening in an ideal 
health care system.
The public health sector should, as a matter of 
urgency and priority, continue to implement the 
current cytological screening programme. It is also 
recommended that the age of  rst smear should be 
shifted to the left, probably to age 25. The South African 
Human Papillomavirus Advisory Board previously 
also recommended that Government should explore 
alternative screening strategies, including HPV testing.
Cytology and HPV vaccination
HPV vaccination in women with existing cytological 
anomalies has no bene t. Cytology, as a prerequisite 
before vaccination, is also not recommended. 
Cytological screening of HPV-vaccinated women is 
recommended and required, as protection is not 100%. 
HPV testing and HPV vaccination
HPV DNA or antibody testing prior to vaccination is 
not recommended to prove or disprove prior HPV 
exposure. HPV antibody testing has no current clinical 
application and need not be performed to prove an 
immune response. 
The use of HPV DNA testing as a primary screening 
test may be more appropriate in the vaccine era and, 
as triage with cytology, will still be an applicable 
screening option in the post-vaccination era. (See 
recommendations by the South African Human 
Papillomavirus Advisory Board ).
The South African Human Papillomavirus Advisory 
Board was established in August 2005 as an 
independent advisory group of clinicians and 
scientists, considered to be opinion leaders in 
the  eld of gynaecological oncology and cervical 
cancer epidemiology and screening. The Board is 
a  liated to SASOG and SASGO and is supported 
logistically by several companies with an interest in 
HPV-related disease. The members of the Board do 
not declare any con§ ict of interest. The opinions and 
recommendations expressed in this document do 
not re§ ect the policy of any company or the opinion 
of any individual board member, and is not meant to 
be prescriptive or legally binding. 
 
These guidelines are intended and presented as 
summarised information for health care providers 
and managers, interpreted with South African data 
and conditions in mind, on which to base clinical 
decision making. This document represents the  rst 
major revision of the vaccine document published 
in 2008 and will continue to be revised. For the 
references of this guideline summary, please consult 
the webpage of SAJGO.
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